Itch-free state in patients with atopic dermatitis treated with ruxolitinib cream: A pooled analysis from two randomized phase 3 studies

Abstract

To the Editor: Atopic dermatitis (AD), a highly pruritic, chronic inflammatory skin disease, affects patients' quality of life.1,2 Previous reports identified itch as a significant symptom in adults and children with AD, with adults reporting it as the most burdensome symptom.2,3 In 2 identically designed phase 3 studies (TRuE-AD1/TRuE-AD2), ruxolitinib cream demonstrated anti-inflammatory and antipruritic activity and was well tolerated.4 Here, we evaluated the achievement of an itch-free state using pooled data from these studies.